Objectives: Few single latency-reversing agents (LRAs) have been tested in vivo, and only some of them have demonstrated an effect, albeit weak, on the decrease of latent reservoir. Therefore, other LRAs and combinations of LRAs need to be assessed. Here, we evaluated the potential of combined treatments of therapeutically promising LRAs, disulfiram and romidepsin. Results: We demonstrated heterogeneous reactivation effects of disulfiram in vitro in various cell lines of myeloid origin and no latency reversal neither in vitro in T-lymphoid cells nor ex vivo, even if doses corresponding to maximal plasmatic concentration or higher were tested. Disulfiram+romidepsin combined treatments produced distinct reactivation patterns in vitro. Ex vivo, the combined treatments showed a modest reactivation effect when used simultaneously as opposed to no viral reactivation for the corresponding sequential treatment.
INTRODUCTION
Combination antiretroviral therapy (cART) has profound health benefits for people with HIV, but cART is not curative and patients must stay on therapy indefinitely. Persistence during cART of latently infected cells containing integrated, transcriptionally silent but replication-competent proviruses is a major hurdle for HIV-1 eradication. 1 Although many cells may contribute to the latent reservoirs, including monocytes and monocyte-derived macrophages (reviewed in 2, 3 ), the best characterized one is a small population of long-lived HIV-1-infected resting memory CD4 + T cells, maintained throughout patient's life by homeostatic proliferation. 4 The absence of viral gene expression in latently infected cells renders the virus imperceptible to host immune response. However, various cellular stimuli can induce the latent reservoirs, allowing for HIV-1 transcription and subsequent production of replication-competent virus, 5, 6 which can represent one potential source of rebound of viremia after cART interruption. 7 One proposed strategy for eliminating the latent reservoir is to pharmacologically stimulate HIV-1 gene expression in latently infected cells, rendering these cells susceptible to cytolytic T lymphocytes or viral cytopathic effects while maintaining cART to prevent new spreading infection. 8 Small molecule latencyreversing agents (LRAs) with potential therapeutical application as shock agents have been identified including antialcoholism drug disulfiram (DSF) 9, 10 and histone deacetylase inhibitors (HDACIs) such as SAHA, panobinostat, and romidepsin. [11] [12] [13] Such compounds also include protein kinase C agonists (prostratin, bryostatin, and ingenols), 14, 15 bromodomain and extraterminal domain inhibitors (JQ1, I-BET, and I-BET151), 6 histone methyltransferases inhibitors (chaetocin and BIX0194), 16 DNA methyltransferase inhibitors or demethylating agents (5-AzadC), 5 and toll-like receptor 7 agonists (GS-9620). 17 DSF has been used for the treatment of chronic alcoholism for more than 60 years. 18 In vitro studies showed that DSF reactivates HIV in latently infected cell lines of myeloid but not T-lymphoid origin 19 and in primary Bcl-2-transduced CD4 + T-cell model of latency. 20 A pilot clinical study using an FDA-approved dose showed no overall effect on plasma HIV RNA during DSF administration, but a transient increase in plasma HIV RNA was noted in a post hoc analysis in some patients. 9 Importantly, a dose-escalation study showed very good safety profile of DSF, a clear dose-dependent effect of disulfiram on HIV transcription; however, a small effect on plasma HIV-1 RNA only for the highest dose was observed. 10 In addition to antilatency clinical trials using DSF, several trials using HDACIs have been reported in the HIV field. 12, 13 Romidepsin, an HDACI, was also evaluated in vivo and was shown to be the most potent latency activator tested in clinical trials to date. 13 However, despite its potent effect, no decrease in the reservoir size was observed. Altogether, these studies using LRAs are encouraging but question the efficacy of LRAs used alone to reduce the size of the HIV-1 reservoirs. Combination of different classes of LRAs targeting different mechanisms of latency can exhibit synergistic effect (ie, result in a higher reactivation level than the sum of the reactivations produced by each compound individually) in reactivation of HIV expression in latently infected cells. We and others have demonstrated proof of concepts for the coadministration of 2 different classes of LRAs 5,6,21 as a therapeutic perspective to decrease the pool of latent HIV-1 reservoirs in the presence of efficient cART.
In this study, we turned our attention to 2 therapeutically promising LRAs, DSF and romidepsin, since the former showed excellent safety profile and the latter potent reactivation in vivo. We evaluated the reactivation potential of individual and combined treatments of DSF and romidepsin in multiple in vitro cellular latency models and in ex vivo cultures of CD8 + -depleted peripheral blood mononuclear cells (PBMCs) isolated from HIV + aviremic cART-treated individuals.
RESULTS

Heterogeneous Effects of DSF on HIV Reactivation In Vitro in Latently Infected Cell Lines
We first determined optimal concentration of DSF in terms of both HIV-1 reactivation potential and effect on the cellular viability. We measured induction of HIV-1 p24 capsid protein production and cellular metabolic activity in wellstudied HIV-1 latency cellular model, promonocytic U1 cell line. Increasing doses of DSF for 24, 48, and 72 hours augmented p24 antigen level in the cell supernatants in a doseand time-dependent manner from 5 to 20 mM (Fig. 1A) . We also assessed the effect of the increasing doses of DSF on cell viability as measured by WST-1 assay that reflects the cell metabolic activity and cell proliferation. We observed doseand time-dependent effect on cellular viability for DSF doses ranging from 20 to 50 mM (Fig. 1B) . We therefore determined that 10 mM of DSF for 48 hours was optimal in terms of both reactivation effect and effect on cellular viability.
We next assessed the reactivation effect of increasing doses of DSF in 2 other monocytic-derived cell lines containing latent HIV-1 proviruses, that is, THP89GFP and CHME-5/HIV microglial cells. These cell lines containing a reporter GFP were treated with increasing doses of DSF for 24, 48, and 72 hours (Figs. 1C and E) . In THP89GFP cells, 20 mM of DSF for 24 hours was optimal in terms of both reactivation effect and effect on cellular viability. Interestingly, in the CHME-5/HIV cell line, we observed 2 peaks of reactivation (at 0.5 and 10 mM), and the reactivation effect was the most pronounced after 24-hour stimulation with strong decrease in reactivation after 48 and 72 hours of DSF treatment (Fig. 1E) . Moreover, cytotoxicity was observed from 20 mM DSF (Fig. 1F) .
Finally, we also assessed the reactivation effect of increasing doses of DSF in a T-lymphoid Jurkat cell-based latency model, the J-Lat 9.2 cell line treated for 24, 48, and 72 hours (Fig. 1G) . We observed no induction of HIV-1 gene expression in this cell line at any DSF concentration used and at any time-point tested as compared to TNFalpha treatment (see Figure 1 , Supplemental Digital Content, http://links.lww. com/QAI/B273). DSF presented no negative effect on cellular viability for concentrations of DSF up to 20 mM treated for 24 and 48 hours (Fig. 1H ). In addition, no HIV reactivation could be observed in 2 other Jurkat-based latency model cell lines, that is, A2 and A72 cells (see Figure 2 , Supplemental Digital Content, http://links.lww.com/QAI/B273). Importantly, Doyon et al 19 has also reported that DSF reactivates HIV-1 expression in the U1 but not in Jurkat-based cell line latency models. They have shown that DSF significantly reduces phosphatase and tensin homolog (PTEN) protein levels in U1 cells. They have observed that Jurkat cell-based models of latency do not express PTEN, explaining the lack of DSF effect on HIV-1 expression in these cell lines. Notably, we could not observe any expression levels of PTEN protein neither in J-Lat 9.2 nor in monocytic-derived U1 and THP89GFP cells (see Figure 3 , Supplemental Digital Content, http://links.lww.com/QAI/B273), but we detected PTEN in CHME-5/HIV microglial cell line.
In conclusion, our results demonstrated that the in vitro reactivation effect of DSF was heterogeneous with distinct reactivation patterns within myeloid-derived latency cell lines and no reactivation was observed in T-lymphocytic-based latency cell lines.
Distinct In Vitro Reactivation Patterns After DSF+Romidepsin Combined Treatments in Myeloid HIV Latently Infected Cell Lines
We next investigated whether DSF could synergistically reactivate HIV-1 expression when combined with romidepsin in either U1 or THP89GFP or CHME-5/HIV cell lines. Two compounds synergize when their combination produces higher effect than the sum of effects arising from separate treatments. We tested DSF at 0.5, 10, and 20 mM (concentrations we determined to be optimal doses in latency models we investigated). In addition, we also investigated DSF at 2 and 5 mM. Romidepsin was tested at 2 concentrations 0.0175 and 0.04 mM that correspond to dose previously established by our laboratory 5 and to plasmatic concentration achieved in patients after romidepsin administration, 13 respectively.
Since, in U1 cells, we observed time-dependent effect of DSF with optimal timing at 48 hours, we investigated both simultaneous and sequential DSF+romidepsin combined treatments. We compared a simultaneous treatment in which DSF and romidepsin were added together for 48 hours with a sequential treatment in which 24-hour DSF pretreatment was followed by a 24-hour romidepsin induction, corresponding to a total of 48-hour DSF treatment. By extracellular p24 ELISA assays, we observed that simultaneous DSF+romidep-sin treatments exhibited overall only additive effects ( Fig. 2A , max. fold synergy = 1.1) as compared to sequential treatment that produced synergistic effects (Fig. 2B , max. fold synergy = 3.4). Of note, 48-hour romidepsin treatment was very toxic (90% of reduction in cellular viability) as compared to 24-hour romidepsin treatment (60% of reduction in cellular FIGURE 2. A, Regarding simultaneous treatment, at 48 hours post-DSF and romidepsin treatments viral production was estimated by measuring CA-p24 antigen concentration in culture supernatants. The mock-treated value was arbitrarily set at a value of 1. Means and standard errors of the means from triplicate samples are indicated. B, Regarding sequential treatment, at 24 hours post-romidepsin treatment and 48h post-DSF treatment, viral production was estimated by measuring CA-p24 antigen concentration in culture supernatants. C and D, Additionally cellular viability was assessed by WST-1 assay that reflects cell metabolic activity, proliferation and cytotoxicity. For each combinatory treatment, the fold-synergy was calculated by dividing the effect observed after co-treatments by the sum of the effects obtained after the individual treatments. viability) (Figs. 2C, D, respectively) . Worth mentioning, we observed very high synergistic reactivation effects of sequential treatments in which DSF was combined with some other HDACIs (see Figure 4A , Supplemental Digital Content, http://links.lww.com/QAI/B273) and other classes of LRAs (see Figure 4B , Supplemental Digital Content, http://links. lww.com/QAI/B273).
Next, we evaluated whether DSF could synergize with romidepsin in THP89GFP and CHME-5/HIV cell lines. We investigated only the simultaneous combined treatments in these cell lines, since DSF reactivation effect was only observed after 24 hours of treatment. Regarding THP89GFP cells, we observed synergistic increase in the GFP-positive cells after simultaneous cotreatments of 20 mM DSF with either romidepsin at 0.0175 mM or at 0.04 mM (Fig. 3A , fold synergy = 2.1 and fold synergy = 2.3, respectively). Marginal effects on cellular viability were observed (Fig. 3B) . In case of CHME-5/ HIV cells, we observed only modest synergistic increase in the GFP-positive cells after simultaneous DSF+romidepsin combined treatments as compared to individual treatments (Fig. 3C, fold synergy ,2) . Cytotoxicity was observed for 20 mM DSF and the DSF+romidepsin combined treatments (Fig. 3D) .
In conclusion, our results demonstrated that DSF+ro-midepsin combined treatments produced various synergistic effects, and the highest synergistic effects were observed in U1 cells after sequential DSF+romidepsin treatment.
Simultaneous But Not Sequential
To address the reactivation potential of the simultaneous and sequential DSF+romidepsin treatments in ex vivo cultures, we firstly evaluated the cytotoxic effects of those treatments on cells from healthy donors. We observed that DSF alone was not toxic and the combined treatments produced cytotoxic effects ranging from 20% to 60% as assessed by cellular viability tests (see Figure 5 , Supplemental Digital Content, http://links.lww.com/QAI/B273). Then, CD8 + -depleted PBMCs isolated from 18 cART-treated aviremic HIV-1 + patients were mock-treated, treated with antiCD3+anti-CD28 antibodies as a positive control for global T-cell activation or with indicated compounds added in a simultaneous or sequential manner alone or in combination (see Fig. 4 and Table S1 , Supplemental Digital Content, http://links.lww.com/QAI/B273). HIV-1 genomic RNA concentrations in culture supernatants were quantified after 6 days of drug(s) treatment (Table 1) . We observed in mocktreated cultures a recovery in viral genomic RNA (mean of 928 HIV-1 RNA copies/mL) that could be explained by activation of HIV-infected cells during the purification procedure or during the course of experiment. Importantly, we observed that DSF at 2 mM (that corresponds to plasmatic concentration reported by Elliot et al 10 ) and DSF at 5 mM (that has been chosen by us in this ex vivo study) showed no additional increase in mean HIV-1 RNA levels as compared to mock-treated cells (597 HIV-1 RNA copies/ml and 646 HIV-1 RNA copies/mL, respectively). However, these changes were not statistically significant (see Table S2 , Supplemental Digital Content, http://links.lww.com/QAI/ B273). Furthermore, 2 doses of romidepsin were selected for the ex vivo study: a dose of 0.0175 mM that was determined in 5 and a dose of 0.04 mM that corresponds to plasmatic concentration measured in HIV reactivation clinical trial. 13 Romidepsin at 0.0175 and 0.04 mM that was added at day 1 exhibited statistically significant increases in HIV recovery (mean of 1925 HIV-1 RNA copies/mL and 2546 HIV-1 RNA copies/mL, respectively, Fig. 4 , see Table S2 , Supplemental Digital Content, http://links.lww.com/QAI/ B273). Romidepsin at 0.0175 and 0.04 mM that was added at day 3 produced lower HIV recovery (mean of 1275 HIV-1 RNA copies/mL and 1617 HIV-1 RNA copies/mL, respectively, Fig. 4 ) that was not statistically relevant (see Table S2 , Supplemental Digital Content, http://links.lww.com/QAI/ B273). Combined simultaneous DSF+romidepsin treatments exhibited increases in extracellular HIV-1 RNA levels that were higher than their corresponding individual treatments (Fig. 4) . Those increases were statistically significant when compared either with mock or individual DSF treatments, but no significance could be observed for comparisons with corresponding individual romidepsin treatment (see Table S2 , Supplemental Digital Content, http://links.lww.com/QAI/ B273). Of note, simultaneous combination of 5 mM DSF and 0.04 mM romidepsin induced the highest mean HIV RNA levels; however, this recovery was not statistically relevant when compared with romidepsin individual treatment (see Fig. 4 and Table S2 , Supplemental Digital Content, http://links.lww.com/QAI/B273).
Moreover, sequential DSF+romidepsin treatments did not exhibit any positive and statistically relevant effects on extracellular HIV-1 RNA levels (see Fig. 4 and Table S2 , Supplemental Digital Content, http://links.lww.com/QAI/ B273).
In addition to the increases in mean extracellular HIV-1 RNA levels, we demonstrated a higher viral production in several cell cultures after combined treatments (Table 1 , see italicized and bold values).
In conclusion, our results demonstrated that individual DSF and sequential DSF+romidepsin treatments did not reactivate HIV from latency ex vivo in CD8 + -depleted PBMCs from HIV + cART-treated aviremic individuals. Importantly, individual romidepsin treatments produced statistically significant HIV recoveries. Moreover, simultaneous DSF+romidepsin treatments produced only moderate beneficial reactivation effects. 
DISCUSSION
A number of chemical compounds have been identified as HIV LRAs. DSF has also been studied and brought forward to clinical trials. 9, 10 In this report, we evaluated reactivation potential of DSF alone or combined with romidepsin in vitro in various latency cell lines of myeloid and T-lymphocytic origins and ex vivo in CD8 + -depleted PBMCs from HIV + aviremic cART-treated individuals. We observed heterogenous DSF reactivation patterns within myeloid-derived latency cell lines and no reactivation was observed in Jurkat-based T-cell line, highlighting different reactivation patterns between models from different cellular lineage but also between models belonging to the same cellular lineage. Importantly, several recent studies have shown that LRAs have limited reactivation spectra, being effective only in some cell types. For instance, recent work from Baxter et al 22 has demonstrated a heterogeneous response of CD4 + population to individual LRAs: bryostatin induced the effector memory CD4 + T-cell reservoir but had limited effect on the central/transitional memory CD4 + T-cell compartment, contrasting with similar effects observed with ingenol. In addition, it has been recently demonstrated by Chen et al 23 that different LRAs reactivate different subsets of latent proviruses. Moreover, we also observed in a previous report a great heterogeneity between patients in terms of reactivation capacity of their ex vivo cell cultures. 24 Altogether, these recent works and our findings strongly suggest that LRAs may have limited and heterogeneous reactivation spectra in vivo due to cellular and viral heterogeneity of latent reservoirs and that multiple mechanisms may be involved in the reactivation of latent HIV. Previously, Doyon et al 19 have investigated the mechanism of DSF action on latent HIV in U1 and Jurkat-based cell lines and have shown that DSF acts through the Akt signaling pathway by decreasing PTEN in U1 cells but not in Jurkat-based cell lines. By contrary, we could not detect PTEN in U1 cells, questioning the role of this factor in DSF-mediated HIV reactivation in this cell line and suggesting a different mechanism. Interestingly, Lin et al 25 have shown that DSF treatment results in demethylation of genes hypermethylated in prostate cancer with subsequent reexpression of these genes, suggesting that DSF can act as an epigenetic drug. It remains to be determined whether DSF could act as epigenetic drug on HIV expression.
Remarkably, we could not observe any reactivation effect of DSF ex vivo, in CD8 + -depleted PBMCs isolated from HIV + aviremic cART-treated individuals. This could be explained at least partially by the fact that most of the HIVinfected cells in blood are CD4 + T cells with HIV-infected monocytes being extremely low. Although HIV-1 proviral DNA is only present in less than 1% of circulating monocytes (between 0.01% and 1%), these cells are important viral reservoirs and are responsible for the dissemination of HIV-1 into sanctuaries such as the brain. 26 Importantly, in our ex vivo studies, we tested 2 and 5 mM DSF with the former corresponding to max. plasmatic concentration from the recent dose-escalation clinical trial. 10 This study showed that even if all doses (500, 1000, and 2000 mg) produced an increase at the level of intracellular HIV RNA, only the highest dose increased the plasma HIV RNA albeit with very low effect. This effect was extremely modest and an order of magnitude lower than that noted previously with HDACI, romidepsin. 13 In line with this observation, Mohammadi et al 27 have also previously shown in their primary CD4 + T-cell models that DSF treatment successfully increases viral transcription, but fails to effectively enhance viral translation, as the levels of viral-encoded GFP remained low, suggesting the importance of post-transcriptional block(s) as one mechanism leading to HIV latency that needs to be relieved to purge the viral reservoir. It is therefore very likely that DSF may not generate a cellular environment that effectively sustains HIV particle production ex vivo. Similar observation has been reported for SAHA, that is, weak effect at the level of viral particle production in vivo. 11 Notably, a clear change in plasma HIV-1 RNA with subsequent decrease in the reservoir size has been seen in vivo only for romidepsin (combined with immunotherapy) 28 and for check point inhibitor nivolumab. 29 Importantly, no study so far affected time from interruption of cART to viral rebound. These observations and recent studies demonstrating cell-type specificity of LRAs suggest that to achieve high levels of latency reversal, combinations of mechanistically distinct LRAs that exhibit broad spectra of reactivation (being active in multiple cell types) most likely combined with immunotherapy may be required.
In this report, we tested combined treatments of DSF and romidepsin. This LRA combination is of particular clinical interest. DSF has an excellent safety profile given the long history of chronic use for alcohol dependence. Romidepsin has also been evaluated in vivo, and the magnitude of HIV-1 induction after romidepsin administration is greater than anything previously reported for any LRA tested in humans. 13 We evaluated simultaneous and sequential combined treatments of those 2 promising LRAs in vitro and ex vivo. Moreover, with the purpose to find the optimal conditions for synergistic studies, we evaluated several concentrations of both LRAs including doses corresponding to maximal plasmatic concentrations, achieved in clinical trials, for both LRAs. Importantly, we observed significant synergistic effects only in U1 cells, and only modest addictive effect was observed ex vivo. Laird et al 21 have also observed that DSF+romidepsin combined treatments did not produce synergistic but only modest additive effect in ex vivo cultures of resting CD4 + T cells from infected individuals; however, lower dose of DSF (0.5 mM) has been tested in this study. Here, for synergistic ex vivo studies, we evaluated higher doses of DSF, 2 and 5 mM, with the former corresponding to max. plasmatic concentration from the recent dose-escalation clinical trial.
In summary, cell-type-specific and distinct reactivation patterns of DSF highlight the heterogeneity of HIV reservoirs and that multiple molecular mechanisms contribute to HIV latency that need to be relieved to reach a cure. Notably, demonstration of weak ex vivo reactivation effect of combined DSF+romidepsin treatments should be considered for designing future clinical trials and suggest that to achieve high levels of latency reversal, combination
